Skip to main content

and
  1. No Access

    Chapter and Conference Paper

    Incidence and Severity of Amphotericin B-induced Acute Toxicity in Leukemic Patients After Treatment with Three Different Formulations (Amphotericin B, AmBisome and Amphotericin B/lntralipid) — A Pilot Study

    Intravenous amphotericin B (AmB) is the most potent drug for treatment of systemic fungal infections in leukemic patients. However, use of this drug is often limited by renal side effects and acute toxicity (f...

    M. Arning, K. O. Kliche, A. Wehmeier, A. H. Heer-Sonderhoff in Acute Leukemias V (1996)